Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval of breast cancer drug Kisqali
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
The American Journal of Managed Care
3d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (
Kisqali
) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early
breast
cancer
. The FDA approved ribociclib (
Kisqali
) with an aromatase ...
pharmaphorum
2d
Lilly on alert as new Kisqali approval threatens Verzenio
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Kentucky judge fatally shot
$230 million crypto theft
Secret Service probing post
FCC chair denies Trump call
Boy kills bear, saves father
Cancels appearance w/ Duda
Families lose appeal
Ban called for in TX schools
Body found in SUV
To get a second moon
NYC subway joyride arrest
Man charged for threats
Hold campaign event in MI
Stein's ballot bid rejected
Disney to stop using Slack
Collapse hazard recall
Recalling 449K+ vehicles
MS sheriff's office probe
Vows to remain in race
Raises settlement offer
PGA welcomes LIV players
'Targeted strike' in Beirut
$3B for battery projects
FTC on privacy controls
Brazil threatens daily fines
To visit US next week
COVID, Wuhan market link
160M euros to Ukraine
Overdose deaths drop in US
Makes MLB history
Related topics
Food and Drug Administration
Ribociclib
Feedback